Pyxis Oncology IncNASDAQ:PYXS
- LAST PRICE4.6800
- TODAY'S CHANGE (%)-0.1500 (-3.1056%)
- Bid / Lots4.6700/ 3
- Ask / Lots4.6900/ 2
- Open / Previous Close4.8600 / 4.8300
- Day Range
- 52 Week Range
- Volume120,759
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PYXS |
|---|---|---|
| 09:32 ET | 2963 | 4.86 |
| 09:34 ET | 100 | 4.78 |
| 09:38 ET | 1646 | 4.83 |
| 09:41 ET | 3800 | 4.78 |
| 09:43 ET | 200 | 4.78 |
| 09:45 ET | 7395 | 4.78 |
| 09:48 ET | 1200 | 4.71 |
| 09:50 ET | 1400 | 4.735 |
| 09:52 ET | 100 | 4.71 |
| 09:56 ET | 3487 | 4.75 |
| 09:57 ET | 2683 | 4.7605 |
| 09:59 ET | 1400 | 4.8 |
| 10:08 ET | 700 | 4.79 |
| 10:14 ET | 2599 | 4.7501 |
| 10:15 ET | 518 | 4.77 |
| 10:19 ET | 300 | 4.775 |
| 10:21 ET | 1300 | 4.76 |
| 10:24 ET | 1352 | 4.73 |
| 10:26 ET | 6300 | 4.75 |
| 10:28 ET | 100 | 4.755 |
| 10:30 ET | 901 | 4.79 |
| 10:32 ET | 500 | 4.77 |
| 10:33 ET | 100 | 4.75 |
| 10:39 ET | 200 | 4.745 |
| 10:42 ET | 633 | 4.74 |
| 10:48 ET | 975 | 4.75 |
| 10:50 ET | 192 | 4.75 |
| 10:51 ET | 1452 | 4.75 |
| 10:57 ET | 7428 | 4.725 |
| 11:00 ET | 1877 | 4.68 |
| 11:02 ET | 600 | 4.705 |
| 11:08 ET | 2893 | 4.73 |
| 11:11 ET | 300 | 4.72 |
| 11:13 ET | 1225 | 4.705 |
| 11:15 ET | 574 | 4.715 |
| 11:18 ET | 200 | 4.72 |
| 11:20 ET | 200 | 4.72 |
| 11:22 ET | 987 | 4.74 |
| 11:24 ET | 784 | 4.73 |
| 11:27 ET | 4857 | 4.74 |
| 11:29 ET | 3295 | 4.72 |
| 11:31 ET | 951 | 4.72 |
| 11:33 ET | 745 | 4.74 |
| 11:36 ET | 1760 | 4.75 |
| 11:38 ET | 200 | 4.755 |
| 11:40 ET | 400 | 4.74 |
| 11:42 ET | 823 | 4.745 |
| 11:44 ET | 2058 | 4.72 |
| 11:45 ET | 200 | 4.725 |
| 11:47 ET | 100 | 4.73 |
| 11:49 ET | 700 | 4.73 |
| 11:51 ET | 600 | 4.75 |
| 11:56 ET | 6285 | 4.75 |
| 11:58 ET | 1831 | 4.75 |
| 12:00 ET | 120 | 4.75 |
| 12:03 ET | 12166 | 4.703 |
| 12:05 ET | 574 | 4.7 |
| 12:09 ET | 808 | 4.68 |
| 12:12 ET | 1900 | 4.68 |
Apr 10, 2024
DJ Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:20AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:20AM ET on Wednesday Apr 10, 2024 by Dow Jones
Mar 28, 2024
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Thursday Mar 28, 2024 by Dow Jones
4:30PM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 27, 2024
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights, from 7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 22, 2024
DJ Pyxis Oncology Price Target Maintained With a $7.00/Share by RBC Capital, from 10:58AM ET on Friday Mar 22, 2024 by Dow Jones
10:58AM ET on Friday Mar 22, 2024 by Dow JonesDJ Pyxis Oncology Is Maintained at Buy by HC Wainwright & Co., from 6:26AM ET on Friday Mar 22, 2024 by Dow Jones
6:26AM ET on Friday Mar 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pyxis Oncology Inc | 280.8M | -2.5x | --- |
RAPT Therapeutics Inc | 279.8M | -2.6x | --- |
Nanobiotix SA | 262.0M | -3.0x | --- |
Verastem Inc | 274.3M | -2.6x | --- |
Inozyme Pharma Inc | 287.2M | -3.4x | --- |
Opthea Ltd | 273.6M | -1.4x | --- |
Company Information
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.
Contact Information
- Headquarters
- 321 Harrison Avenue, 11th Floor, Suite 1BOSTON, MA, United States 02118
- Phone
- 617-453-3596
- Fax
- 302-655-5049
Executives
- Independent Chairman Of The Board
- John Flavin
- Chief Executive Officer, Director
- Lara Sullivan
- Chief Financial Officer, Chief Operating Officer
- Pamela Connealy
- Chief Medical Officer
- Ken Kobayashi
- Independent Director
- Thomas Civik
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $280.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.87 |
Book Value | $2.81 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
